JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3007 ABT-263 (Navitoclax)
15 Citation

Target: Bcl-2|Bcl-w

Summary: Potent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w

≥48.73 mg/mL
A2604 Celastrol

Target: Proteasome

Summary: Antioxidant, anti-inflammatory and immunosuppressive agent

≥22.55 mg/mL
A4116 Danusertib (PHA-739358)
2 Citation

Target: Aurora Kinases

Summary: Pan-aurora kinase inhibitor

≥23.75 mg/mL
A4208 NSC 319726

Target: p53

Summary: Reactivator of mutant p53
A4211 Lenalidomide (CC-5013)

Target: angiogenesis

Summary: Antineoplastic agent,inhibits angiogenesis

insoluble in EtOH; insoluble in H2O; ≥100.8 mg/mL
A4212 Pomalidomide (CC-4047)

Summary: Immunomodulator,antumor/anti-angiogenic

insoluble in EtOH; insoluble in H2O; ≥7.5 mg/mL
A4221 YM155
2 Citation

Target: Survivin

Summary: Survivin suppressant,apoptosis inhibitor

≥22.15 mg/mL
A4224 GDC-0152
2 Citation

Target: Inhibitor of apoptosis proteins (IAP)

Summary: IAP antagonist,potent amd samll-molecule

≥24.95 mg/mL
A4228 Nutlin-3

Target: MDM2

Summary: MDM2 antagonist,inhibits MDM2-p53 interaction

≥58.2 mg/mL
A4234 TW-37
1 Citation

Target: Bcl-2|Bcl-xl|Mcl-1

Summary: Bcl-2 inhibitor, inhibits Bcl-2,Bcl-XL and Mcl-1

insoluble in H2O; ≥19.75 mg/mL